Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPO for Cognitive Impairment in Bipolar and Depression
NCT03315897Phase 2Completed
- Start
- Jul 2017
- Primary completion
- Oct 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of erythropoietin in bipolar disorder (BD) and major depressive disorder (MDD) (2 arms). Primary endpoint: Cognitive composite score at 13 weeks. Started Jul 2017; status: completed.
02
Drugs
erythropoietin
03
Conditions
bipolar disorder (BD)major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03315897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03315897.